{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:27:01Z","timestamp":1785583621612,"version":"3.56.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"DOI":"10.7759\/cureus.83380","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T06:56:51Z","timestamp":1746255411000},"source":"Crossref","is-referenced-by-count":1,"title":["Abemaciclib-Associated Panniculitis With Fibrosis: Expanding the Dermatologic Spectrum of Cyclin-Dependent Kinase 4\/6 Inhibitors"],"prefix":"10.7759","author":[{"given":"Varsha","family":"Pujala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravya","family":"Balmuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharwat","family":"Ghattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millicent","family":"Amankwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj kumar","family":"Posa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge GW Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, et al.. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017, 35:2875-84. 10.1200\/JCO.2017.73.7585","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13691","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo HS","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, et al.. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021, 26:e522. 10.1002\/onco.13691","journal-title":"Oncologist"},{"key":"ref3","article-title":"Dermatopathology evaluation of panniculitis","author":"Lee J","year":"2024","unstructured":"Lee J, Sathe NC. Dermatopathology evaluation of panniculitis. StatPearls. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2016.12.004","article-title":"Panniculitis: a summary","volume":"34","author":"Wick MR","year":"2017","unstructured":"Wick MR. Panniculitis: a summary. Semin Diagn Pathol. 2017, 34:261-72. 10.1053\/j.semdp.2016.12.004","journal-title":"Semin Diagn Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review","volume":"44","author":"Silvestri M","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A, et al.. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf. 2021, 44:725-32. 10.1007\/s40264-021-01071-1","journal-title":"Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA Adverse Event Reporting System","volume":"23","author":"Raschi E","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E, De Ponti F. Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA Adverse Event Reporting System. Am J Clin Dermatol. 2022, 23:247-55. 10.1007\/s40257-021-00645-0","journal-title":"Am J Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2022.11.013","article-title":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice","volume":"150","author":"Sibaud V","year":"2023","unstructured":"Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice. Ann Dermatol Venereol. 2023, 150:208-12. 10.1016\/j.annder.2022.11.013","journal-title":"Ann Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143658","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV Task Force \u201cdermatology for cancer patients\u201d international study","volume":"15","author":"Sollena P","year":"2023","unstructured":"Sollena P, Vasiliki N, Kotteas E, et al.. Cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV Task Force \u201cdermatology for cancer patients\u201d international study. Cancers (Basel). 2023, 15:3658. 10.3390\/cancers15143658","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57677","article-title":"Abemaciclib-associated skin, hair, and nail toxicities: a case report","volume":"16","author":"Alsatti H","year":"2024","unstructured":"Alsatti H, AlMalki B, Alghamdi Y. Abemaciclib-associated skin, hair, and nail toxicities: a case report. Cureus. 2024, 16:e57677. 10.7759\/cureus.57677","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.092","article-title":"Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4\/6 inhibitor use","volume":"86","author":"Amigo M","year":"2022","unstructured":"Amigo M, Hoffman K, Chung C, et al.. Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4\/6 inhibitor use. J Am Acad Dermatol. 2022, 86:1346-8. 10.1016\/j.jaad.2021.04.092","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359168-abemaciclib-associated-panniculitis-with-fibrosis-expanding-the-dermatologic-spectrum-of-cyclin-dependent-kinase-46-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T06:56:51Z","timestamp":1746255411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359168-abemaciclib-associated-panniculitis-with-fibrosis-expanding-the-dermatologic-spectrum-of-cyclin-dependent-kinase-46-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.83380","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}